GlaxoSmithKline Spotlights Immune System And Oncology R&D
Two-Year Effort To Refocus Research Pipeline Bearing Fruit
New oncology and immunology products are moving rapidly through GSK’s refocused research pipeline, including new agents for multiple myeloma, endometrial and head and neck cancer, adding to efforts against COVID-19, respiratory syncytial virus infection and HIV/AIDS.
You may also be interested in...
GlaxoSmithKline sees initial signs of recovery from the coronavirus pandemic in terms of vaccination rates and highlights its growing research progress against COVID, RSV and meningitis, although a UK expert warns against over-optimism.
Benefits of the BCMA-directed antibody-drug conjugate outweigh its ocular risks in heavily pretreated multiple myeloma patients, Oncologic Drugs Advisory Committee says at the conclusion of a virtual meeting beset by technical problems.
Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.